European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Novavax, Inc. (Nasdaq: NVAX), […]
